Delving into the Latest Updates on Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.) with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

Recombinant Human Granulocyte Colony-Stimulating Factor, 重组人粒细胞刺激因子（北京四环生物制药）, Xin Lisheng

+ [1]

Target

CSF-3R

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication

Neutropenia

Inactive Indication-

Originator Organization

Beijing Four Rings Biopharmaceutical Co. Ltd.

Active Organization

Beijing Four Rings Biopharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (17 Jun 2002),

Neutropenia

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 4190

This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.

Start Date01 Aug 2024

Sponsor / Collaborator

Lishui Central Hospital

[+11]

ChiCTR-INR-16010071 / RecruitingIIT

Effect of Priming with Recombinant Human Granulocyte ColonyeStimulating Factor on low dose Decitabine combined with Busulfex and Cyclophosphamide for High-Risk Acute Myeloid Leukemia Patients Undergoing Human Leukocyte Antigene Matched Hematopoietic Stem Cell Transplantation:A Multicenter,Open,Randomized controlled trial

Start Date15 Dec 2016

Sponsor / Collaborator

Xinqiao Hospital

100 Clinical Results associated with Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.)

Login to view more data

100 Translational Medicine associated with Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.)

Login to view more data

100 Patents (Medical) associated with Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.)

Login to view more data

207

Literatures (Medical) associated with Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.)

01 Mar 2023·JDS Communications

Pegbovigrastim use in periparturient embryo-recipient cows: Effects on health and reproduction

Article

Author: Wang, S ; Cortes, D ; Chirivi, M ; Contreras, G A

The objective of this randomized clinical study was to evaluate the effects of periparturient administration of pegbovigrastim (recombinant bovine granulocyte colony stimulating factor; PEG) on postpartum health and reproductive outcomes in dairy cows carrying transferred embryos. A total of 60 multiparous Jersey cows (second parity n = 21, >second parity n = 39) that were in vitro-fertilized embryo recipients were enrolled. Animals were selected from a commercial herd and assigned to 1 of 2 treatments: (1) PEG (n = 31), which received a subcutaneous injection of 15 mg of PEG 7 d before expected calving and a second dose within 1 h of parturition; or (2) CON, untreated control (n = 29). Parturition was induced pharmacologically in all cows at 280 d of pregnancy with 500 μg of cloprostenol and 25 mg of dexamethasone intramuscularly. Cow health was monitored daily during the periparturient period and included assessment for retained fetal membranes within 24 h after calving and metritis until 20 d in milk. Descriptive statistics were calculated, to determine the incidence of postpartum diseases, causes of culling, and early-lactation reproductive outcomes, including number of inseminations, days to first heat, days to first service, and interval from calving to conception. The Wilcoxon rank sum test was used to assess treatment effects on early-lactation reproductive performance outcomes. The overall incidence of metritis in this cohort of cows was 17.14%. Animals treated with PEG tended to have more cases of metritis (25%) compared with CON (8.8%). Mastitis incidence in PEG was 19.35% compared with CON at 27.59%. These data suggest that in this dairy, with embryo-recipient cows induced to calve at 280 d of pregnancy, the administration of 2 doses of PEG tended to increase postpartum metritis but had no effect on mastitis incidence, culling rate, or early-lactation reproductive outcomes.

01 Dec 2022·eClinicalMedicine

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

Article

Author: Birudaraju, Divya ; Gutierrez, Rebecca ; Morgan, Timothy R. ; MacHarg, Lauren ; Zarick, Cory ; Hamal, Sajad ; Chao, Daniel C-K. ; Donovan, John A. ; Kaplowitz, Neil ; Head, Preston ; Cherukuri, Lavanya ; Gonzalez, Rachel ; Nguyen, Danh V. ; Stolz, Andrew A. ; Tayek, John A. ; Jones, Carol ; Rico, Christy ; Asghar, Aliya ; Milstein, Susan ; Lee, Robert ; Fleischman, M. Wayne ; Alcorn, Joseph M. ; Buddha, Hema ; Gozum, Jessica ; Cruz, Sheena ; Ouyang, Yuxin ; Botwin, Greg ; French, Monique

BackgroundIn trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH). The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a long-acting recombinant GCSF, in patients with AH in the United States.MethodsThis prospective, randomized, open label trial conducted between March 2017 and March 2020 randomized patients with a clinical diagnosis of AH and a Maddrey discriminant function score ≥32 to standard of care (SOC) or SOC+pegfilgrastim (0.6 mg subcutaneously) on Day 1 and Day 8 (clinicaltrials.gov NCT02776059). SOC was 28 days of either pentoxifylline or prednisolone, as determined by the patient's primary physician. The second injection of pegfilgrastim was not administered if the white blood cell count exceeded 30,000/mm³ on Day 8. Primary outcome was survival at Day 90. Secondary outcomes included the incidence of acute kidney injury (AKI), hepatorenal syndrome (HRS), hepatic encephalopathy, or infections.FindingsThe study was terminated early due to COVID19 pandemic. Eighteen patients were randomized to SOC and 16 to SOC+pegfilgrastim. All patients received prednisolone as SOC. Nine patients failed to receive a second dose of pegfilgrastin due to WBC > 30,000/mm³ on Day 8. Survival at 90 days was similar in both groups (SOC: 0.83 [95% confidence interval [CI]: 0.57-0.94] vs. pegfilgrastim: 0.73 [95% CI: 0.44-0.89]; p > 0.05; CI for difference: -0.18-0.38). The incidences of AKI, HRS, hepatic encephalopathy, and infections were similar in both treatment arms and there were no serious adverse events attributed to pegfilgrastim.InterpretationThis phase II trial found no survival benefit at 90 days among subjects with AH who received pegfilgrastim+prednisolone compared with subjects receiving prednisolone alone.Fundingwas provided by the United States National Institutes of Health and National Institute on Alcohol Abuse and Alcoholism U01-AA021886 and U01-AA021884.

01 Sep 2022·Lung India

Autoimmune pulmonary alveolar proteinosis and sarcoidosis in the same patient

Author: Bal, Amanjit ; Shrestha, Deepa ; Agarwal, Ritesh ; Muthu, Valliappan ; Sehgal, Inderpaul S ; Dhooria, Sahajal

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by surfactant accumulation in the alveolar spaces while sarcoidosis is a multisystem granulomatous disease of unknown etiology. The occurrence of PAP and sarcoidosis in the same patient is rare. A 37-year-old woman presented with cough and breathlessness and was diagnosed to have autoimmune PAP. She responded well to subcutaneous injections of recombinant granulocyte macrophage colony stimulating factor. Three years later, she developed fever, chest pain, cough, and facial palsy. The evaluation revealed a diagnosis of sarcoidosis that responded to immunosuppressive treatment. We discuss the link between PAP and sarcoidosis and review the literature on this association.

100 Deals associated with Recombinant human granulocyte colony stimulating Factor(Beijing Four Rings Biopharmaceutical Co. Ltd.)

Login to view more data